[1] |
LIU Lijing, QIAN Hong, MENG Qingxin, ZHANG Xiang, HE Bin, HE Jianbin, WEI Yingmin.
Sinomenine inhibits oxidative stress and pulmonary fibrosis by activating the Keap1/Nrf2 signaling pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 979-987.
|
[2] |
LI Shixu, LI Linyun, WANG Xin, LI Ke, BIAN Hua.
Effects of Ginkgo biloba extract on renal injury in rats with experimental renal failure through miR-145/FOXO1 axis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 728-735.
|
[3] |
LI Yating, YUE Hongmei, LIU Miaomiao, XU Jinhui, WU Xingdong, ZHU Haobin.
The possibility of phosphodiesterase 4 inhibitors as drug therapy for idiopathic pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 818-823.
|
[4] |
NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang.
Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
|
[5] |
ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen .
Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
|
[6] |
LIU Nanyu, YUE Hongmei, SONG Peipei, WEI Jifang, WEI Yaqian, XIE Yingying, WANG Jiaqi .
PDE4 inhibitors serve as therapeutic targets for pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 355-360.
|
[7] |
MA Yue, MA Wangbo, ZHOU Zhihua, CHANG Jingwen, FAN Fangtian.
Intervention of quercetin in glycolysis of renal interstitial fibroblasts against interstitial fibrosis mechanism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 121-129.
|
[8] |
WANG Jie, LI Long, CHEN Feng, LIU Shengfei.
Research progress of metformin in the pathogenesis of pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 235-240.
|
[9] |
SHEN Chang, AI Kelong, HU Changping.
Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
|
[10] |
ZHOU Huan, XU Ming, LI Bo, LIU Chunying, WANG Chun.
PI3K/Akt/FOXO3a signaling pathway inducing protective autophagy promotes acquired lung adenocarcinoma resistance remodeling to DDP
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 961-970.
|
[11] |
DING Jiamin, WANG Youdi, ZHAO Xiali, JIANG Genfeng, CHEN Siwen, HONG Chengcheng, LI Shuqin, HU Weihua.
Study on the treatment of thin endometrium with growth hormone and vitamin E
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 857-862.
|
[12] |
FU Hong, TIAN Lei.
Individualized precision therapy for patients with ischemic stroke and hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
|
[13] |
WU Lijun, Li Xin, CUI Lijuan, LI Xinxin, WANG Yan.
Amelioration of nebivolol on renal interstitial fibrosis in UUO rats based on proteomic analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 729-738.
|
[14] |
WEI Feng, HE Yang, FAN Zhiqiang, LIU Shikun, OUYANG Linqi.
Inhibitory effect of flufenidone on TGF-β1/Smads pathway in hepatocytes of rats with diethylnitrosamine (DEN)-induced liver injury
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 739-746.
|
[15] |
CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong.
Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
|